Zenas BioPharma (ZBIO) Projected to Post Quarterly Earnings on Thursday

Key Points

• Zenas BioPharma is set to announce its Q2 2025 earnings on August 21st, with analysts predicting a loss of ($1.02) per share and revenue of $1.25 million.
• The company's shares rose by 5.1% and have a market capitalization of approximately $698.98 million, with recent price movements reflecting a 1-year low of $5.83 and a high of $26.25.
• Research analysts have reaffirmed strong ratings for Zenas BioPharma, with price objectives of $30.00 and $35.00 from HC Wainwright and Wedbush, respectively.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 21st. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $1.25 million for the quarter.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Zenas BioPharma Trading Up 0.1%

ZBIO stock traded up $0.02 during midday trading on Monday, reaching $16.84. 111,375 shares of the company were exchanged, compared to its average volume of 178,919. Zenas BioPharma has a 1-year low of $5.83 and a 1-year high of $26.25. The company's 50-day moving average price is $12.74. The company has a market capitalization of $709.13 million and a P/E ratio of -4.74.

Analyst Ratings Changes

A number of research firms recently issued reports on ZBIO. Wall Street Zen downgraded Zenas BioPharma from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Zenas BioPharma in a research note on Friday, May 16th. Finally, Wedbush restated an "outperform" rating and set a $35.00 price target on shares of Zenas BioPharma in a research note on Thursday, May 15th.

Institutional Trading of Zenas BioPharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock valued at $3,621,000 after buying an additional 16,461 shares during the period. Sei Investments Co. acquired a new position in Zenas BioPharma in the 2nd quarter valued at $118,000. Rhumbline Advisers increased its stake in Zenas BioPharma by 71.3% in the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company's stock valued at $191,000 after buying an additional 8,207 shares during the period. Finally, Bank of America Corp DE increased its stake in Zenas BioPharma by 32.3% in the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock valued at $136,000 after buying an additional 3,412 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.